Anebulo Pharmaceuticals, Inc.
ANEB · OTCMCIK 1815974fmd_0ERX4T52AY7KZPDZPBC7AMBV0ZManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2020 to Dec 31, 2025, 22 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Research and development | 2 | 3 | 6 | 4 | 4 |
| Total operating expenses | 4 | 7 | 12 | 8 | 9 |
| Operating income | (4) | (7) | (12) | (8) | (9) |
| Interest expense | 0 | – | – | 0 | 0 |
| Interest and investment income | 0 | – | – | – | – |
| Other non-operating income (expense) | (27) | 0 | 0 | 0 | 1 |
| Income before taxes | (4) | – | – | – | – |
| Net income | (30) | (7) | (12) | (8) | (8) |
| Net income to common shareholders | (38) | (7) | – | – | – |